newsfilter.io
Sep 14, 2026, 4:04 PM ETHealthcare

Benitec Biopharma — Full Year 2026 Earnings Summary

BNTCBENITEC BIOPHARMA INC
Source

Financial Performance

  • Total expenses for the year ended June 30, 2026, were $51.2 million, an increase from $41.8 million in the prior year.
  • Research and development expenses were $23.4 million in 2026, up from $18.3 million in 2025, driven by higher share-based compensation ($6.3 million increase) and increased payroll ($2.2 million increase), partially offset by reduced contract manufacturing activity ($3.8 million decrease).
  • General and administrative expenses totaled $27.8 million in 2026 compared to $23.4 million in 2025, primarily due to higher share-based compensation ($2.7 million increase) and increased payroll ($0.8 million increase).
  • Net loss from operations was $51.2 million in 2026 compared to $41.8 million in 2025.
  • Net loss attributable to shareholders was $45.5 million ($0.98 per share) in 2026, compared to $37.9 million ($1.05 per share) in 2025.
  • Cash and cash equivalents were $180.0 million as of June 30, 2026, compared to $97.7 million in the prior year.
  • Total assets were $182.6 million as of June 30, 2026, compared to $99.6 million in 2025.
  • Total liabilities were $5.6 million as of June 30, 2026, compared to $2.3 million in 2025.
  • Interest income, net, was $5.6 million in 2026, up from $3.3 million in 2025.

Guidance and Future Outlook

  • The Company anticipates initiating the BB-301 pivotal trial in mid-2027.
  • Meeting minutes from the Type C meeting with the FDA regarding the BB-301 pivotal study design are anticipated in October 2026.
  • Management expressed confidence in the potential of BB-301 to alter the course of OPMD-related dysphagia based on observed clinical benefit consistency and durability.

Business Segments and Product Lines

  • BB-301 is the lead investigational candidate, a disease-modifying genetic medicine for Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia.
  • All six patients in Cohort 1 (low dose BB-301) have completed the full 12-month post-treatment follow-up period.
  • Cohort 2 (high dose BB-301) is fully enrolled with all three patients safely treated.
  • Interim clinical results for Cohort 1 and Cohort 2 will be presented at the 33rd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in Hamburg, Germany, October 27-30, 2026.
  • Clinically meaningful improvements were observed in patient-reported swallowing symptoms and X-ray based swallowing function evaluations, including improved throat closing, emptying, muscle relaxation, and functional swallowing ability.
  • BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA.

Market and Competitive Landscape

  • BB-301 is described as the first and only disease-modifying genetic medicine in clinical development for the treatment of OPMD-related dysphagia.
  • The proprietary "Silence and Replace" ddRNAi platform combines RNA interference with gene therapy to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes.

Risks and Challenges

  • The press release includes a standard list of forward-looking statement risks, including potential delays in clinical trials, failure to meet regulatory standards, inability to secure additional financing, and risks related to intellectual property, manufacturing, and market acceptance.
  • Specific risks mentioned include the uncertainty of achieving profitability, the potential for unsuccessful clinical trial results, and dependence on third-party manufacturers and suppliers.

Management Commentary and Tone

  • Jerel A. Banks, M.D., Ph.D., Executive Chairman and CEO, described the year as an "important year of clinical execution."
  • Management stated that discussions with the FDA regarding pivotal study plans strengthen their conviction in BB-301's potential.
  • The tone was confident, citing the consistency and durability of clinical benefits and gratitude toward patients and investigators.

Other Key Points

  • A Type C meeting with the U.S. FDA was held in the third quarter of 2026 to discuss the BB-301 pivotal study design.
  • The Company reported a net loss per share decrease from $1.05 in 2025 to $0.98 in 2026 despite higher total expenses, attributed to an increase in the weighted average number of shares outstanding (from 36.2 million to 46.6 million).
  • The Company holds Orphan Drug and Fast Track designations from the FDA for BB-301.